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ST-elevation myocardial infarction (STEMI) is one of the leading causes of mortality 
and morbidity worldwide. While the survival after acute STEMI has considerably 
improved, mortality rate still remains high, especially in high-risk patients. Survival 
after acute STEMI is influenced by clinical characteristics such as age as well as the 
presence of comorbidities. However, during emergency care increasing access to 
tools such as the electrocardiogram, chest x-ray and echocardiography can provide 
additional information helping to further risk stratify patients. In the invasive setting, 
this can also include coronary angiography, invasive hemodynamic recordings and 
angiographic assessments of coronary flow and myocardial perfusion. We outline the 
common investigations used in STEMI and their role in risk assessment of patients with 
an acute STEMI.
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ST-elevation myocardial infarction (STEMI) 
is one of the leading causes of mortality and 
morbidity worldwide. However, survival after 
acute STEMI has considerably improved due 
to increasing symptom recognition, accurate 
diagnosis and effective timely reperfusion [1]. 
Further reasons for reduction in STEMI 
mortality can be explained by greater use of 
percutaneous coronary intervention (PCI), 
antithrombotic therapy and secondary car-
diovascular prevention strategies [1–3]. The 
incidence of STEMI has seen a general decline 
in recent years [4]. Despite this, mortality 
remains substantial with approximately 12% of 
patient’s dead within 6 months and with higher 
mortality rates noted in high-risk patients [5].
Survival after an acute STEMI is influenced 
by characteristics such as age, comorbidities 
(diabetes mellitus [DM], hypertension, pre-
vious myocardial infarction [MI] and renal 
failure), multivessel disease (MVD), left ven-
tricular (LV) ejection fraction (EF) and timely 
revascularization (thrombolysis and/or PCI).
STEMI definition
STEMI is a part of a spectrum of acute coro-
nary syndromes (ACS), which also include 
non-STEMI (NSTEMI) and unstable angina 
(UA). The European Society of Cardiology 
(ESC) guidelines define STEMI as a rise 
and/or fall in cardiac biomarkers with at least 
one of the following symptoms of ischemia, 
new ST changes or new left bundle branch 
block, appearance of pathological Q waves, 
imaging evidence of loss of viable myocardium 
and finally the confirmation of intracoronary 
thrombus by coronary angiography [1].
Initial presentation
Clinical characteristics
Early risk assessment at the time of the 
first medical contact is important. Clini-
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cians should consider the age of the patient, history of 
comorbidity and examination findings including vital 
signs and presence of heart failure (HF) (Figure 1).
Gender, age, comorbidities & Killip 
classification
Increasing age and presence of comorbidities have 
been recognized as critical factors in predicting clini-
cal outcome in patients with STEMI. Comorbidities 
leading to higher incidence of early mortality include 
existing coronary heart disease, DM, renal disease, 
peripheral vascular disease and HF. A large cohort 
study (n = 28,421) in Korea conducted by Park et al. 
found that independent predictors of early mortality in 
STEMI patients included old age above 60 years old, 
Killip class, female gender, LV dysfunction and renal 
failure [6]. Another study by Pederson et al. revealed 
that DM, in addition to age and HF, were found to be 
independent predictors of early mortality in STEMI 
patients [7]. The prognostic value of gender has been 
a controversial topic in STEMI patients. Some studies 
have shown female gender to be an independent pre-
dictor for mortality in STEMI patients. For example, 
a large observational study in Paris by Benamer et al., 
which included 16,760 STEMI patients, demonstrated 
that female gender is independently associated with 
higher inpatient mortality rate in a multivariate analy-
sis [8]. Conversely, a multihospital study by Kyto et al. 
on 31,689 STEMI patients revealed that the differ-
ences in in-hospital mortality between genders were 
caused by differences in age and comorbidities and not 
due to gender itself [9].
The Killip classification, which categorizes patients 
based on the severity of HF (Killip class I – no evi-
dence of HF, through to Killip class IV – cardiogenic 
shock), has been a valuable tool for early risk strati-
fication in STEMI. The Global Registry of Acute 
Coronary Events (GRACE) investigators evaluated 
16,166 acute MI patients and demonstrated that HF 
on admission was associated with four-times greater 
risk of in-hospital mortality, across all ACS subsets [10].
Cardiogenic shock & Glasgow Coma Scale
Cardiogenic shock (hypotension, inotrope, vasopressor 
or intra-aortic balloon pump use or end-organ hypo-
perfusion) occurs in approximately 5% of STEMI 
patients and is associated with an in-hospital mortality 
rate of 38% [11]. Examination findings, such as heart 
rate and blood pressure on admission have predictive 
value on the short-term clinical outcomes post PCI in 
STEMI. They have been used in several risk assessment 
tools including GRACE and thrombus in myocardial 
Figure 1. Routine investigations used in ST-elevation myocardial infarction patients in clinical practice. 
CFR: Coronary flow reserve; IMH: Intramural hematoma; IMR: Index of microcirculatory resistance; 
MPO: Myeloperoxidase; MVO: Microvascular obstruction; TIMI: Thrombolysis in myocardial infarction.
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infarction (TIMI) score. A low systolic blood pressure 
(<100 mmHg) and high heart rate (>100 bpm) are 
associated with poor short-term clinical outcomes. An 
observational study on 2310 STEMI patients treated 
with primary PCI showed that increased heart rate on 
admission was an independent prognostic factor for 
in-hospital and long-term mortality [12,13].
The finding of a new murmur is an indicator of a 
structural complication of STEMI, which may lead 
to acute HF. STEMI with inferior ischemia can lead 
to papillary muscle dysfunction causing mitral regur-
gitation, which results in new pansystolic murmur. It 
rarely occurs with anterior or lateral ischemia due to 
the dual blood supply to the anterolateral papillary 
muscle. Ischemic mitral regurgitation is a common 
complication of STEMI and has been known to be 
an independent strong predictor of long-term mortal-
ity [13]. However, no studies have proven that mitral 
regurgitation in STEMI is associated with adverse 
short-term clinical outcomes. Acute septal rupture is 
a life threatening complication that can present with 
cardiogenic shock, biventricular failure and new pan-
systolic murmur, usually within the first week post MI.
A prospective study by Lettieri et al., which included 
2617 patients with STEMI treated with emergency 
PCI in 2005, found that a Glasgow Coma Scale (GCS) 
score of 3 was an independent predictor of in-hospital 
mortality [14]. This result was consistent with a China-
based study by Pan et al., which demonstrated that 
GCS ≤7 and cardiogenic shock, on admission were 
independent predictors of early mortality, in patients 
with out-of-hospital cardiac arrest [15]. Both studies also 
showed that long-term mortality risks in these patients 
were similar to those without prehospital cardiac arrest. 
However, it is possible that the consequential adverse 
short-term outcomes may be confounded by cardiac 
arrest events. There is still uncertainty in the role of 
the GCS score on admission for risk stratification.
In-hospital course
Coronary angiography
Extent of coronary artery disease
Around 40–50% of patients presenting with STEMI 
have MVD and these patients have been consistently 
shown to have worse cardiac risk profiles than patients 
with single-vessel disease [16]. Many early studies 
(before the stenting era) found the presence of MVD 
to be a predictor of 30-day or in-hospital mortality, 
independent of other cardiovascular risk factors [17]. 
However, since the introduction of stenting, the asso-
ciation between MVD and short-term outcome is less 
convincing. Sorajja et al. found a higher frequency of 
recurrent ischemia in MVD patients at 30 days, but a 
nonsignificant trend toward death and major adverse 
cardiac events (MACE) at 30 days [16]. Similarly, 
Dziewierz et al. saw that patients with MVD had an 
increased risk of ischemic events, bleeding at 30 days 
and an association with 30-day mortality that was 
dependent on cardiogenic shock [18].
The prognostic significance of MVD in assess-
ing acute risk may be dependent on the presence of 
a chronic total occlusion (CTO) [19]. In a study of 
3277 STEMI patients conducted in Amsterdam, the 
presence of a CTO in a noninfarct related artery was 
a strong predictor of 30-day mortality (hazard ratio 
[HR]: 3.6 [95% CI: 2.6–4.7]; p < 0.01), while MVD 
without a CTO was a comparably weaker predic-
tor (HR: 1.1 [95% CI: 0.8–1.5]; p = 0.01) [19]. These 
results were further replicated in the HORIZON-AMI 
patient cohort [20]. Current evidence suggests that the 
early prognostic value of MVD in assessing risk may be 
driven by the presence of CTO and cardiogenic shock.
Similarly the presence of multiple complex plaques, 
identified on angiography, and defined as more than 
one lesion with two or more defining features of a 
complex plaque, are associated with MACE and major 
bleeding at 30 days [21]. Additionally, these patients are 
more likely to require urgent bypass surgery [21]. Multi-
variable analysis confirms that the presence of multiple 
complex plaques is an independent predictor of 3-year 
MACE [21].
Hemodynamics: LV end-diastolic pressure, 
central venous pressure & right heart, pulmonary 
capillary wedge pressure
While there have been studies to suggest that hemo-
dynamic measures can predict 30-day mortality 
and infarct size (IS), the evidence of the prognostic 
value of hemodynamic measures in STEMI patients 
is limited [22], partly because right heart catheteriza-
tion is no longer performed due to associated risks. 
LV end-diastolic pressure is frequently measured at 
PCI, however, and has been shown to be an indepen-
dent predictor of in-hospital death, cardiogenic shock 
and HF [23]. Furthermore, LV end-diastolic pressure 
>18 mmHg predicts death and re-infarction 30 days 
post STEMI [24,25].
Left ventriculography
LV involves the injection of radiographic dye via a 
multisidehole pigtail catheter inserted retrogradely 
through the aortic valve into the LV to assess LV 
function and volume [26]. The procedure provides 
information on wall motion, LV thrombus (LVT), 
mitral regurgitation, aneurysms and ventricular sep-
tal defects (VSDs) as well as aids the diagnosis of 
Takotsubo cardiomyopathy, an STEMI mimic [26]. 
However, the procedure poses significant risks to 
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the patients, including longer radiation exposure, 
increased contrast use, embolization or myocardial 
rupture [26]. Furthermore, there are alternate noninva-
sive methods for measuring LV volumes and function, 
including cardiac MRI and echocardiography [26]. 
Moreover, left ventriculography has shown variable 
performance when compared with echocardiography 
in patients with MI [27]. While left ventriculography 
is a low-cost procedure and may be of use when LV 
function is unknown, its routine use as a prognostic 
indicator in STEMI is not indicated.
Angiographic assessments of coronary flow 
& myocardial perfusion
TIMI flow grade
The TIMI flow grade (TFG) is an angiographic mea-
sure of flow in an epicardial artery and is graded 0, 1, 
2 or 3 (0 – no flow; 1 – minimal flow past obstruc-
tion; 2 – slow but complete filling and slow clearance; 
3 – normal flow and clearance) (Table 1). Corrected 
TIMI frame count is a more objective and quantitative 
index of coronary flow, which is calculated by count-
ing the number of cineframes needed for dye to reach 
standardized distal landmarks [28].
TFG before intervention has been studied in detail 
in the context of pharmacological and mechanical 
interventions to achieve patency in the culprit artery. 
Notably, STEMI patients with TFG 2–3 in the cul-
prit artery after thrombolysis and before mechanical 
intervention, were seen to have higher rates of TFG 3 
post procedure, smaller ISs, better predischarge 
LVEFs, shorter hospital stays and lower risk of car-
diogenic shock [25,29]. In addition, patients presenting 
with culprit TFG 2–3 have been shown to have bet-
ter 30-day survival compared with those with TFG 
0–1 [25,29].
TFG post procedure has been consistently shown 
to be associated with in-hospital mortality in STEMI 
patients, including in specific subpopulations of 
cardiogenic shock patients and elderly patients 
(≥75 years) [30,31]. Studies also report higher rates of 
30-day mortality and 30-day MACE in patients with 
impaired TFG after intervention [32]. Post procedural 
TFG is also included in both the CADILLAC score 
and Angiographic Perfusion Score (TFG + TIMI myo-
cardial perfusion grade [TMPG]), which both predict 
30-day mortality [33]. There is a wealth of evidence to 
suggest that the TFG, both before and after interven-
tional treatment, is an indicator of MI severity and 
short-term outcomes.
Myocardial perfusion & the no-reflow 
phenomenon
Angiographic successful reperfusion in acute MI has 
been defined as TIMI 3 flow. However, TIMI 3 flow 
does not always result in effective myocardial reperfu-
sion. Myocardial blush grade is an angiographic mea-
sure of myocardial perfusion and is therefore used to 
assess perfusion in the capillary bed at the tissue level. 
The TIMI blush grade is an ordinal score for contrast 
washout at the end of the angiogram, and the TIMI 
blush grade is also predictive of prognosis.
Gibson et al., first assessed the associations with 
TMPG in a large cohort of patients (n = 762) and 
reported that patients with TMPG 0 had a higher 
mortality rate at 30 days compared with those with 
TMPG 1, 2 or 3 [34]. Importantly, the association 
held true when restricted to patients with TFG 3, 
anterior MI and patient characteristics such as age 
and gender [34]. Later studies associated a low TMPG 
post revascularization with the incidence of an isch-
emic event within 48 h [35], and ventricular arrhyth-
mia within 30 days of thrombolysis [36]. In addition, 
TMPG has been shown to be in concordance with the 
extent of ST-segment resolution after treatment for 
STEMI. While associations with both absolute and 
relative ST-segment changes were significant, they 
were weak suggesting other factors may be relevant.
Index of microcirculatory resistance
Coronary guidewire-based sensor technologies have 
emerged as new diagnostic tools for the invasive assess-
ment of coronary artery disease in the setting of ACS. 
The index of microvascular resistance (IMR) is a simple 
coronary guidewire-based method for assessing coro-
nary microvascular function and is a direct measure 
of microvascular resistance. IMR measured directly 
after primary PCI predicts IS [37] and functional recov-
ery [38]. In a landmark recent study, 253 acute STEMI 
patients with IMR >40 had a higher rate of the pri-
mary end point of death or rehospitalization for HF at 
1 year than patients with an IMR ≤40 (17.1 vs 6.6%; 
Table 1. Thrombolysis in myocardial infarction 
blush grade.
TIMI blush grade Definition
0 No myocardial blush
1 Minimal blush and very slow 
clearing (e.g., present at the 
beginning of next cine)
2 Good blush with slow clearing 
of myocardial contrast (present 
at the end of cine but gone at 
the beginning of next)
3 Good blush and normal clearing 
(i.e., gone by the end of cine)
TIMI: Thrombolysis in myocardial infarction.
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p = 0.027) [39]. IMR is promising for early risk strati-
fication in acute reperfused STEMI survivors, since it 
is readily available in the catheter laboratory, quantita-
tive and reproducible. On the other hand, evidence is 
lacking that treatment decisions linked to IMR result 
in clinical benefit, and in this regard, more research is 
warranted.
Coronary flow reserve
Coronary flow reserve (CFR) is another coronary 
guidewire-based method, which reflects epicardial 
and microvascular vasodilator capacity. CFR is more 
amenable to hemodynamic changes and is less repro-
ducible than IMR [40]. Nevertheless, Cuculi et al., 
showed that change in CFR in the first day after pri-
mary PCI was associated with 6-month LVEF and 
myocardial salvage (MS) [41]. Van de Hoef et al. found 
that in 157 STEMI survivors, a CFR <2.0 was associ-
ated with MACE over a 10-year period [42]. Prior stud-
ies of IMR and CFR are limited by sample size, short 
follow-up and differences in cut-offs, supporting the 
case for further research.
Post reperfusion (coronary care unit)
ECG
ECG monitoring should be continuous throughout 
initial reperfusion period, and a 12-lead ECG should 
be acquired 60–90 min post reperfusion to asses for 
successful myocardial perfusion. This should show 
resolution of ST elevation and hyperacute T-waves. 
Indeed, the extent of early resolution of ST segment 
has been linked to IS and EF [43]. On the contrary 
persistent ST-elevation after reperfusion may be associ-
ated with need for further interventions due to more 
extensive myocardial damage and a higher mortal-
ity rate [43]. Furthermore, ECG reperfusion provides 
a real-time physiological marker of cellular perfusion 
and is a significant predictor of LV contractility recov-
ery. Ideally, there needs to be continuous ECG record-
ing to monitor segment resolution. Early reperfusion of 
the terminal portion of T-waves after the initiation of 
reperfusion therapy is another indicator of successful 
reperfusion.
Plasma biomarkers
Cardiac troponin: standard assay (μg)  
& high-sensitivity assay (ng/l)
The sensitivity and specificity of different commer-
cially troponin assays vary considerably relating to 
lack of standardization, different use of monoclo-
nal antibodies and the presence of modified tropo-
nin I (TnI) and troponin T (TnT) in the serum. The 
National Academy of Clinical Biochemistry (NABC) 
working with ESC and American Heart Association 
(AHA) has recommended adoption of 99th percen-
tile upper reference limit as the recommended cut 
off for a positive troponin result, based on findings 
from the GUSTO IV and TACTICS-TIMI 18 trial. 
An elevated troponin at baseline is an independent 
predictor of mortality even in patients with chest 
pain and STEMI who were eligible for reperfusion 
therapy [44,45]. The GUSTO 11A, GUSTO IV ACS 
and FRISC trial all demonstrated a direct correlation 
between the level of TnI or TnT and the incidence of 
cardiac morbidity and death post ACS [45]. In essence 
troponin rise post revascularization has been associ-
ated with IS and LVEF and therefore has a role in risk 
stratification and prognosis.
Other plasma biomarkers
There are several other plasma biomarkers includ-
ing C-reactive protein (CRP), N-terminal pro-brain 
natriuretic peptide (NT-proBNP), cardiac troponin T 
and I, glucose which may have a role for risk stratifica-
tion in STEMI. However, most of these markers are 
limited since there is a delay in enzymatic rise. For 
example, an elevated troponin can occur as early as 
2–3 h versus 6–9 h in creatine kinase-MB. As such, 
most institutions have relied solely on troponins and 
discontinued the use of other cardiac markers. Nev-
ertheless, creatine kinase-MB assessment at a single 
time point has been shown to be a good predictor 
of IS at 6 months on STEMI patients treated with 
PCI [46].
NT-proBNP concentration correlates with acute 
and chronic IS and myocardial function after AMI. 
Moreover, NT-proBNP concentrations are inversely 
associated with the potential for recovery of LV systolic 
function post AMI [47].
CRP is a nonspecific marker of inflammation, 
which has also been investigated as a potential marker 
in STEMI. Studies have illustrated that CRP predicted 
adverse cardiac events, acute MI and HF [48,49]. How-
ever, since it is a nonspecific marker it limits the use on 
the diagnosis of acute MI, unless used in conjunction 
with troponin or BNP.
Novel cytokines
Myeloperoxidase (MPO) is a leukocyte enzyme and 
has been subject to investigation as a novel cardiac 
marker. This enzyme generates reactant oxidant spe-
cies and has also been linked to plaque instability as 
well as vasoconstriction from nitric oxide depletion. 
Elevated MPO has been shown to independently pre-
dict increased risk for major cardiac events, including 
MI, reinfarction and need for revascularization [50]. 
In fact, plasma MPO levels independently predict 
in-hospital mortality in STEMI patients treated by 
586 J. Comp. Eff. Res. (2016) 5(6) future science group
Review    Ahmed, Carberry, Teng, Carrick & Berry
primary PCI [51].
Galectin-3 plays a role in the intracellular path-
ways of LV remodeling. This is also an emerging 
biomarker strongly associated with mortality already 
approved in the risk stratification of HF [52]. It has 
been shown to be a strong and independent predictor 
for LVEF after 4 months in patients with a first MI. 
When measured following STEMI, a high plasma 
galectin-3 predicts greater 30 days morbidity and 
mortality and increased HF incidence at a median 
of 2 years [53].
Scoring systems
GRACE score
There are several scoring systems in STEMI, allow-
ing clinicians to estimate individual probability of 
unwanted outcomes. In ACS patients, the GRACE 
(or GRACE 2.0 score) can predict the outcomes of 
death, or MI over an extended 1 year and also death 
over a 3-year period from hospital admission. The 
clinical variables include age, heart rate, systolic blood 
pressure, creatinine, congestive HF, cardiac arrest, 
ST-segment deviation and elevated enzyme/cardiac 
biomarkers. The use of the GRACE score is recom-
mended in the ESC guidelines, AHA and American 
College of Cardiology guidelines [1]. The GRACE 
risk score provides the most accurate stratification of 
risk both on admission and at discharge due to its 
good discriminative power [54]. The addition of bio-
markers (e.g., NT-proBNP) has been shown to fur-
ther enhance the discriminative power of the GRACE 
score and improve long-term risk prediction [55]. 
Further risk scoring methods are outlined in Table 2.
Predischarge
Echocardiography
Echocardiography, a noninvasive tool, remains the 
main investigation choice in diagnosing complications 
of MI and evaluating cardiac function MI. Evidence has 
shown that the use of echocardiography predischarge is 
valuable in risk stratification post STEMI [56].
Left ventricular ejection fraction
LVEF measured by echocardiography predischarge 
is a valid indicator of IS and has shown by multiple 
studies to be an established predictor of cardiac 
remodeling and adverse clinical outcome. A prospec-
tive cohort study by Vakili et al. which included 304 
STEMI patients reperfused by primary PCI, showed 
that LVEF ≤50% was associated with high rates of 
in-hospital adverse events including death [57]. LVEF 
has also been postulated to be a predictor of adverse 
cardiac remodeling. A study by Wita et al., has shown 
that a lower LVEF on discharge in STEMI patients 
was independently associated with LV remodeling at 
6 months [58].
LV global longitudinal strain
The use of novel imaging techniques, such as speckle-
tracking echocardiography, allows the measurement 
of LV global longitudinal strain (LVGLS), which is 
an accurate index of global LV function [59]. This has 
been shown to be a potential predictor of LV remodel-
ing in STEMI patients. In a cohort of 1041 primary 
PCI-treated STEMI patients, Joyce et al. showed that 
LVGLS predischarge was independently associated 
with LV dilatation at follow-up as well as a potential 
marker of IS [60]. Furthermore, a study by Munk et al., 
(n = 227) showed that LVGLS measured at day 1 in 
STEMI patients was superior to LVEF in predicting 
30-day IS [61]. Since LVGLS provides a semi-automated, 
quantitative measure of LV function without the use of 
ionizing radiation, contrast media or pharmacological 
stressors, it has proven to be a valuable tool for early 
risk evaluation in STEMI patients.
LV volume
Post infarct remodeling is a complex dynamic pro-
cess which involves global LV enlargement post MI. 
It has been shown by McKay et al., to be associated 
with IS since myocardium loss increases LV loading, 
which stimulates compensatory changes that may 
cause HF [62]. A study by Brzezinska et al., (n = 132) 
has showed that an increase in LV end-diastolic vol-
ume index ≥80 ml/m2 at discharge was an indepen-
dent predictor of progressive LV dilatation in STEMI 
patients [63]. However, this is still controversial, since 
Bolognese et al. have identified that LV end-diastolic 
volume index ≥80 ml/m2 predischarge was not a 
significant predictor of progressive LV dilatation [64].
Complications of MI: LVT, LV aneurysm, papillary 
muscle rupture & VSD
Echocardiography is a readily available tool for the 
immediate diagnosis of STEMI complications. The 
diagnosis of left ventricular thrombus (LVT) has dra-
matically improved with the use of echo-contrast since 
it can detect LVT that is inconclusive on conventional 
echocardiography. Gianstefani et al. has shown the 
possibility of early detection of LVT predischarge in 
STEMI patients [65]. However, it did not demonstrate 
an increased mortality risk in the presence of LVT. 
This result was supported by a retrospective study by 
Garber et al., which showed that LVT was not signifi-
cantly associated with increased mortality in STEMI 
patients [66]. Despite this, early diagnosis of LVT by 
echocardiography is important for early treatment 
and risk stratification, since LVT is associated with 
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increased morbidity [67].
Another complication of MI is the formation of LV 
aneurysm. True aneurysms usually involve the entire 
wall thickness and are described as dyskinetic areas of 
thinned myocardium, while pseudoaneurysms that are 
contained by overlying pericardium, usually a result of 
ventricular wall rupture and are prone to spontaneous 
rupture. Although there is not much literature ana-
lyzing STEMI patients with post MI LV aneurysm, 
Visser et al., found that early aneurysm formation post 
MI is associated with high mortality in the short and 
long term [68].
Cardiac MRI
The duration of a cardiac MRI scan is typically 
30–60 min, therefore, only patients who are well 
enough to lie flat for this length of time may be con-
sidered. Echocardiography is the imaging modality of 
choice in the acutely unwell STEMI patient to assess 
for mechanical complications of MI. However, in stable 
patients, cardiac magnetic resonance (CMR) provides 
information on infarct pathology, as well as LV function 
and volume, which together enable a comprehensive 
assessment of the heart, and its’ potential for recovery, 
after acute STEMI. CMR is a comparatively expensive 
technology, often with limited availability in the clinic. 
As with any test, the use of CMR should be supported 
by evidence of benefit from stratified interventions, and 
in his regard, more research is warranted.
T2-weighted edema imaging for myocardial 
edema
T2-weighted (T2W) imaging depicts myocardial 
edema which results from tissue injury during isch-
emia and reperfusion. Studies into the prognostic 
value of T2W imaging post-STEMI are based on the 
concepts of area-at-risk (AAR) and MS. The myo-
cardial AAR is defined as the entire area of hypoper-
fused myocardium during an MI. A landmark study 
by Aletras et al., showed that, in canines subjected 
to coronary occlusion, the area of hyperintensity on 
T2W imaging was consistently larger than IS mea-
sured by late-gadolinium enhancement (LGE) and 
was consistent with histological measurement of the 
AAR [69]. The AAR could then be divided into areas of 
irreversible ischemia and reversible ischemia.
Myocardial salvage, is defined as the difference 
between the final IS and the AAR, as demonstrated 
by a high T2W signal to indicate myocardial edema 
but no LGE signal to suggest irreversible myocardial 
injury (scar) (Figure 2). This concept is useful in the 
confirmation of recent ischemic injury, since it offers 
the ability to differentiate acute from chronic infarcts. 
Eitel et al., found that in 208 acute STEMI survivors, 
the amount of MS was the strongest inverse predictor 
of major adverse cardiovascular events and mortality 
at 6-month follow-up, when included in a multivari-
able cox regression model with Killip class at admis-
sion, TFG after PCI, LVEF, ST-segment resolution 
and IS [70].
Table 2. Risk scoring methods.
Risk scoring methods Definition
TIMI risk score An additive scoring system using only six variables. It excludes Killip class, heart rate and systolic 
blood pressure as risk factors, leading to an inferior discriminative accuracy as compared with the 
GRACE risk score. However, it is simple to use and strongly correlates with mortality at 30 days
CADILLAC score Predicts 30-day and 1-year mortality after primary PCI using the following identified variables: age 
>65 years (2 points), Killip class 2/3 (3 points), baseline LV ejection fraction (during left 
ventriculography) <40% (4 points), anemia (2 points), renal insufficiency (3 points), triple vessel 
disease (2 points) and post procedural TIMI flow grade (2 points). This criterion excludes high-risk 
patients with recent stroke, known renal dysfunction, cardiogenic shock, complex coronary anatomy 
and those undergoing rescue PCI
PAMI risk score Derived from amalgamated data from various PAMI trials to determine 6-month mortality following 
primary PCI. It comprises of the following: age >75 years (7 points), age 65–75 years (3 points), Killip 
class >1 (2 points), heart rate >100 bpm (2 points), DM (2 points), anterior MI or LBBB (2 points)
SYNTAX score An anatomical model designed to decide on the optimal mode of revascularization in complex 
coronary artery disease, e.g., three-vessel disease or left main stem disease. Despite having a role in 
risk stratifying STEMI patients with PCI, it can be further improved through a combination of clinical 
variables
GUSTO-1 Derived from the GUSTO trial, aims to predict 1-year survival in STEMI patients. Predictors include 
older age lower weight, Killip class, admission lower blood pressure, higher heart rate, QRS duration, 
smoking, history of hypertension or cerebrovascular disease or arrhythmia
DM: Diabetes mellitus; GRACE: Global Registry of Acute Coronary Event; LBBB: Left bundle branch block; LV: Left ventricle; MI: Myocardial infarction; 
PCI: Percutaneous coronary intervention; STEMI: ST-elevation myocardial infarction; TIMI: Thrombolysis in myocardial infarction.
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Late gadolinium enhancement for MVO & IS
LGE differentiates irreversibly damaged (nonvi-
able) myocardium, from myocardium which is sim-
ply stunned following an acute ischemic insult, with 
acute reversible myocardial injury being T2W-edema 
positive but LGE-negative. LGE imaging also has the 
ability to identify microvascular obstruction (MVO). 
The presence of MVO represents more severe isch-
emic injury and is directly correlated with larger 
IS [71]. This can be recognized angiographically as the 
‘no-reflow’ phenomenon, which is defined as a failure 
to perfuse at a microvascular level, despite a fully pat-
ent epicardial artery following revascularization. This 
is well established as a negative prognostic marker 
and is recognized as a central hypo-intense core (as 
shown by the dark zones) within bright regions of 
LGE [70]. Eitel et al. showed that in a large multicen-
tre STEMI population (n = 738) reperfused by pri-
mary PCI, CMR markers of myocardial damage (IS 
and especially MVO) provide independent and incre-
mental prognostic information in addition to clinical 
risk scores and LVEF [70]. Similarly, Van Kranen-
burg et al. showed that in 1025 reperfused STEMI 
patients, the presence of MVO was the strongest inde-
pendent predictor of cardiac death and MACE at 2 
years [72]. Novel quantitative T1 mapping techniques 
show promise for characterization of infarct pathology 
without the use of intravenous contrast agent. Car-
rick et al. showed that tissue pathology revealed by 
native T1 maps had similar prognostic value to MVO 
revealed by LGE CMR [73].
Myocardial hemorrhage with T2*-CMR
Myocardial hemorrhage is a complication of severe 
reperfusion injury in STEMI patients. The patho-
physiology is closely intertwined with MVO; how-
ever, they are distinct entities, detected with different 
imaging sequences [74]. T2* CMR is the current gold 
standard for in vivo assessment of myocardial hem-
orrhage. Myocardial hemorrhage is associated with 
adverse remodeling and adverse health outcomes in 
the longer term [75]. Importantly, the occurrence of 
intramyocardial hemorrhage is prognostically more 
significant than MVO [76]. Indeed, the detection of 
intramyocardial hemorrhage and MVO may have a 
pivotal role in the risk assessment in STEMI survivors.
Conclusion
Patients with acute STEMI are at risk of complications 
acutely and in the longer term. During emergency care, 
clinical judgement and immediately accessible tools, such 
as the ECG, chest x-ray and echocardiography, remain 
standard of care tests. In invasively managed patients, 
adjunctive functional tests, in other words, IMR, CFR, 
provide complementary information to the angiogram. 
Cardiac MRI is the reference test for the assessment of 
infarct pathology and viability. The use of any test for 
risk stratification should be linked with treatment, and 
Figure 2. Two patients with acute ST-elevation myocardial infarction who had cardiac MRI 2 days post-event 
including T2* mapping. Angiography in patient A revealed an acutely occluded large obtuse marginal branch 
(orange arrow). Contrast MRI revealed a lateral infarct with significant microvascular obstruction (orange arrow). 
This corresponded to an area of intramyocardial hemorrhage as revealed by T2* mapping (black arrow). Patient B 
suffered an acute occlusion of the mid segment of the right coronary artery (orange arrow). Contrast MRI 
revealed a small infarct territory (orange arrow) with no intramyocardial hemorrhage visible on the T2* map.
Angiogram Cine MRI T2* map Contrast MRI
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more research is warranted to define evidence-based 
therapeutic interventions with stratified testing.
Future perspective
STEMI is still one of the leading causes of morbidity 
and mortality worldwide. However, due to improved 
detection and timely reperfusion the mortality associ-
ated with STEMI is declining, although a substantial 
proportion of patients still develop chronic cardiac fail-
ure in the longer term. We forecast diagnostic accuracy 
will continue to evolve with the development of increas-
ingly sensitive biomarkers of myocyte damage and LV 
dysfunction, ultimately allowing for a timelier diagnosis 
and prognostication. Coronary guidewire-based sensor 
technologies show promise as a new approach to risk 
assessment at the very earliest stage of acute MI man-
agement in the catheterization laboratory, immediately 
post reperfusion. Another development in the field will 
be the increasing use of noninvasive techniques for 
selected risk stratification in the early post-MI period, 
notably cardiac MRI. Cardiac MRI provides a wealth 
of information, including viability and potential for 
Executive summary
Background
•	 In recent years the mortality associated with ST-elevation myocardial infarction (STEMI) is declining, in part 
through increasing symptom recognition, accurate diagnosis and effective timely reperfusion. Nevertheless, 
mortality still remains substantially high, especially in higher risk patients.
Prehospital course
•	 Initial presentation: early risk assessment at the time of first medical contact is vital and includes patient age, 
history of comorbidities as well as examination findings, including vital signs.
Catheterization laboratory
•	 Angiographic assessments of coronary flow and myocardial perfusion: thrombus in myocardial infarction 
(TIMI) flow is an angiographic measure of flow, with patients having higher TIMI flow grades linked to 
smaller infarct sizes (ISs), better ejection fractions (EFs) and shorter hospital stays. Myocardial blush grade 
is a measure of myocardial perfusion with score of 0 linked to higher mortality rates than compared with a 
myocardial blush grade of 1, 2 or 3.
•	 Coronary guidewire-based sensor technologies are emerging as new diagnostic tools for the invasive 
assessment of coronary artery disease in the setting of acute coronary syndromes. An elevated index of 
microcirculatory resistance at the time of primary percutaneous coronary intervention predicts poor long-term 
outcomes.
Post reperfusion (coronary care unit)
•	 Electrocardiogram monitoring should be continuous and acquired 60–90 min post reperfusion to asses for 
successful myocardial perfusion.
•	 Plasma biomarkers: cardiac troponin is the most commonly used plasma biomarker with an elevated troponin 
at baseline shown to be an independent predictor of mortality. There are several other plasma biomarkers 
including C-reactive protein, N-terminal pro-brain natriuretic peptide, cardiac troponin T and I, glucose which 
may also have a role for risk stratification in STEMI.
•	 Scoring systems: there are several scoring systems in STEMI, allowing clinicians to estimate individual 
probability of unwanted outcomes. The Global Registry of Acute Coronary Events risk score provides the most 
accurate stratification of risk both on admission and at discharge due to its good discriminative power.
Pre discharge
•	 Echocardiography: echocardiography is a noninvasive tool and remains the main investigation choice in 
diagnosing complications of myocardial infarction. Evidence has shown that the use of echocardiography 
predischarge is valuable in risk stratification post STEMI. For example, left ventricular EF measured by 
echocardiography predischarge is a valid indicator of IS and has shown by multiple studies to be an established 
predictor of cardiac remodeling and adverse clinical outcome.
•	 Cardiac MRI: cardiac MRI provides information on infarct pathology, as well as left ventricular function and 
volume, which together enables a comprehensive assessment of the heart, and its’ potential for recovery, 
after acute STEMI. Cardiac MRI can also detect infarct characteristics including myocardial hemorrhage, 
which is a complication of severe reperfusion injury in STEMI patients and is now emerging as an important 
prognostic marker.
Conclusion
•	 Patients with acute STEMI are at risk of complications acutely and in the longer term. During emergency 
care, clinical judgement and immediately accessible tools, such as the ECG, chest x-ray and echocardiography, 
remain standard of care tests. For invasively managed patients, adjunctive functional tests including index of 
microvascular resistance and coronary flow reserve can provide complementary information to the angiogram. 
However, the extent of their full role in the diagnosis and prognosis remains to be validated.
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functional recovery, with a high degree of accuracy and 
also allowing repeat scanning since it uses nonioniz-
ing radiation. Cardiac MRI will play an evolving role 
in STEMI patients, especially through the continuing 
development of novel quantitative mapping techniques, 
allowing for a more objective assessment of myocardial 
injury and better tissue characterization.
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